(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 March 2013 (28.03.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/044215 A9

(51) **International Patent Classification**:
A61K 39/00 (2006.01) ***C07K 16/00*** (2006.01)
C12P 21/08 (2006.01)

(21) **International Application Number**:
PCT/US2012/056886

(22) **International Filing Date**:
24 September 2012 (24.09.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/538,454 23 September 2011 (23.09.2011) US
61/597,409 10 February 2012 (10.02.2012) US
61/692,978 24 August 2012 (24.08.2012) US

(71) **Applicant**: **ONCOMED PHARMACEUTICALS, INC.** [US/US]; 800 Chesapeake Drive, Redwood City, CA 94063 (US).

(72) **Inventors**: **GURNEY, Austin, L.**; 946 Diamond Street, San Francisco, CA 94114 (US). **SATO, Aaron, Ken**; 1636 Albemarle Way, Burlingame, CA 94010 (US). **BOND, Christopher, John**; 511 30th Avenue, San Mateo, CA 94403 (US).

(74) **Agents**: **CALVO, Paul, A.** et al.; Sterne, Kessler, Goldstein & Fox, PLLC, 1100 New York Avenue, NW, Washington, DC 20005 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

(48) **Date of publication of this corrected version**:
3 April 2014

(15) **Information about Correction**:
see Notice of 3 April 2014

WO 2013/044215 A9

(54) **Title**: VEGF/DLL4 BINDING AGENTS AND USES THEREOF

(57) **Abstract**: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.